[go: up one dir, main page]

FI893100L - Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi - Google Patents

Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI893100L
FI893100L FI893100A FI893100A FI893100L FI 893100 L FI893100 L FI 893100L FI 893100 A FI893100 A FI 893100A FI 893100 A FI893100 A FI 893100A FI 893100 L FI893100 L FI 893100L
Authority
FI
Finland
Prior art keywords
acyldeoxyribonucleoside
derivatives
preparation
analogous method
analogous
Prior art date
Application number
FI893100A
Other languages
English (en)
Swedish (sv)
Other versions
FI91764C (fi
FI893100A0 (fi
FI91764B (fi
Inventor
Borstel Reid Warren Von
Michael Kevin Bamat
Original Assignee
Pro Neuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc
Publication of FI893100L publication Critical patent/FI893100L/fi
Publication of FI893100A0 publication Critical patent/FI893100A0/fi
Priority to FI941245A priority Critical patent/FI97891C/fi
Application granted granted Critical
Publication of FI91764B publication Critical patent/FI91764B/fi
Publication of FI91764C publication Critical patent/FI91764C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
FI893100A 1987-10-28 1989-06-26 Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi FI91764C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI941245A FI97891C (fi) 1987-10-28 1994-03-16 Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11592387A 1987-10-28 1987-10-28
US11592387 1987-10-28
PCT/US1988/003824 WO1989003838A1 (en) 1987-10-28 1988-10-27 Acyl deoxyribonucleoside derivatives and uses thereof
US8803824 1988-10-27

Publications (4)

Publication Number Publication Date
FI893100L true FI893100L (fi) 1989-06-26
FI893100A0 FI893100A0 (fi) 1989-06-26
FI91764B FI91764B (fi) 1994-04-29
FI91764C FI91764C (fi) 1994-08-10

Family

ID=22364166

Family Applications (2)

Application Number Title Priority Date Filing Date
FI893100A FI91764C (fi) 1987-10-28 1989-06-26 Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi
FI941245A FI97891C (fi) 1987-10-28 1994-03-16 Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI941245A FI97891C (fi) 1987-10-28 1994-03-16 Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi

Country Status (15)

Country Link
US (1) US6020320A (fi)
EP (2) EP0712629B1 (fi)
JP (2) JP2637534B2 (fi)
KR (1) KR890701609A (fi)
AT (2) ATE142221T1 (fi)
CA (1) CA1329932C (fi)
DE (2) DE3856557T2 (fi)
DK (1) DK174400B1 (fi)
FI (2) FI91764C (fi)
HK (1) HK1004854A1 (fi)
IL (1) IL88204A (fi)
IN (1) IN167609B (fi)
NO (1) NO174392C (fi)
WO (1) WO1989003838A1 (fi)
ZA (1) ZA888083B (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173017B1 (en) 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US6329350B1 (en) * 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6054441A (en) 1987-10-28 2000-04-25 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US6743782B1 (en) * 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
IE980216A1 (en) * 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
CA2444071C (en) * 1991-02-08 2008-10-07 Wellstat Therapeutics Corporation Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
DE69232070T2 (de) * 1991-07-05 2002-06-06 Pro-Neuron, Inc. Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
KR100315890B1 (ko) * 1992-12-08 2002-06-27 마이클 바마트 전신염증및염증성간염치료용피리미딘누클레오티드전구체
US5641758A (en) * 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
KR100290132B1 (ko) 1994-07-01 2001-05-15 마이클 바마트 전신 염증 및 염증성 간염 치료용 피리미딘 누클레오티드 전구체
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US20020006913A1 (en) 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
AU2090099A (en) * 1997-12-16 1999-07-05 William Darwin Garner Reduction of uv induced skin cancer by topical amines
PT1431304E (pt) 1998-08-10 2015-03-09 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP1808177B1 (en) 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
DE10117615A1 (de) * 2001-04-07 2002-10-10 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zur verbesserten Gewinnung von adulten Stammzellen
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
HUE027522T2 (en) 2002-09-13 2016-11-28 Novartis Ag ß-L-2'-Deoxynucleosides for treatment of resistant HBV strains and for combination therapies
AU2008307308C1 (en) 2007-08-16 2014-06-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions containing nucleosides and manganese and their uses
WO2010090723A2 (en) * 2009-02-04 2010-08-12 University Of Georgia Research Foundation, Inc. Methods of inhibiting fibrogenesis and treating fibrotic disease
CA2797716C (en) 2010-04-29 2018-09-11 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847898A (en) * 1969-05-27 1974-11-12 Upjohn Co N4-trihaloethoxy carbonyl arabino-furanosyl cytosine 5'-esters
US3585188A (en) * 1969-06-16 1971-06-15 Takeda Chemical Industries Ltd Process for producing 2'-deoxyuridine
DE1941942A1 (de) * 1969-08-18 1971-03-04 Sylven Bengt Prof Dr Neues pharmazeutisches Mittel
FR2096712A1 (en) * 1970-06-29 1972-02-25 Giraux Georges Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
US3894000A (en) * 1971-01-27 1975-07-08 Upjohn Co Ara-cytidine derivatives and process of preparation
US3975367A (en) * 1971-06-08 1976-08-17 The Upjohn Company Arabinofuranosyl N4 -aminoacyl cytosine containing compounds
DE2147094A1 (de) * 1971-09-21 1973-04-05 Robugen Gmbh Virostatisch wirksames arzneimittel
US3991045A (en) * 1973-05-30 1976-11-09 Asahi Kasei Kogyo Kabushiki Kaisha N4 -acylarabinonucleosides
US4048432A (en) * 1976-05-17 1977-09-13 Parke, Davis & Company 9-(3,5-Di-O-acyl-β-D-arabinofuranosyl)adenine compounds and method for their production
FR2358155A1 (fr) * 1976-07-15 1978-02-10 Lapinet Eugene Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS5791994A (en) * 1980-11-26 1982-06-08 Fuji Kagaku Kogyo Kk 5'-o-(n-alkylcarbamoylalanyl)-5-fluorouridine and its preparation
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
JPS57156418A (en) * 1981-03-19 1982-09-27 Sumitomo Chem Co Ltd Carcinostatic
JPS5849315A (ja) * 1981-09-18 1983-03-23 Mitsui Pharmaceut Inc 抗腫瘍剤
JPS58167589A (ja) * 1982-03-26 1983-10-03 Nissan Chem Ind Ltd ピラゾ−ル誘導体、その製法および該誘導体を含有する除草剤
JPS58167598A (ja) * 1982-03-29 1983-10-03 Tanabe Seiyaku Co Ltd アデノシン誘導体及びその製法
FR2536278A1 (fr) * 1982-11-18 1984-05-25 Dupont Michele Nouvelle composition therapeutique utile notamment pour la cicatrisation des plaies
DE3319282A1 (de) * 1983-05-27 1984-11-29 Gödecke AG, 1000 Berlin Verwendung von adenosin bei der behandlung von herpes
JPS59219235A (ja) * 1983-05-30 1984-12-10 Mitsui Toatsu Chem Inc 消化性潰瘍用剤
DE3481191D1 (de) * 1983-07-20 1990-03-08 Teijin Ltd Antineoplastisches mittel.
JPS6028929A (ja) * 1983-07-28 1985-02-14 Hokuriku Seiyaku Co Ltd ２’−デオキシグアノシンを有効成分とする消化性潰瘍治療剤
JPS6064907A (ja) * 1983-09-17 1985-04-13 Risuburan Prod:Kk 水性ゲル状化粧料
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
FR2556727B1 (fr) * 1983-12-19 1990-01-19 Biostabilex Labo Pharma Nouvelles compositions therapeutiques a base d'adn a haut poids moleculaire et leur procede de preparation
JPS60174797A (ja) 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
AU593271B2 (en) * 1985-07-22 1990-02-08 Teijin Limited Antiviral treatments
US4762823A (en) * 1985-10-16 1988-08-09 Sloan-Kettering Institute For Cancer Research Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil
DE3751974T2 (de) * 1986-09-22 1997-04-10 Janssen Pharmaceutica Nv Serotonin-Antagonisten zur Behandlung von Wunden
US4758533A (en) * 1987-09-22 1988-07-19 Xmr Inc. Laser planarization of nonrefractory metal during integrated circuit fabrication
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
JP2638949B2 (ja) * 1988-07-06 1997-08-06 トヨタ自動車株式会社 誘導電導機の制御方法
JPH0628929A (ja) * 1992-07-09 1994-02-04 Fujikura Ltd 絶縁電線
JPH0634913A (ja) * 1992-07-15 1994-02-10 Oki Electric Ind Co Ltd 密着イメージセンサの光学構成方法
JP3251060B2 (ja) * 1992-08-18 2002-01-28 電気化学工業株式会社 窒化珪素粉末
JPH06123917A (ja) * 1992-08-24 1994-05-06 Fuji Photo Film Co Ltd 写真作製装置
JP3454951B2 (ja) * 1994-12-12 2003-10-06 株式会社半導体エネルギー研究所 半導体装置の作製方法

Also Published As

Publication number Publication date
IL88204A0 (en) 1989-06-30
JPH07267981A (ja) 1995-10-17
IL88204A (en) 1996-06-18
DE3856557T2 (de) 2004-06-03
FI91764C (fi) 1994-08-10
NO174392C (no) 1994-04-27
NO892642L (no) 1989-08-24
WO1989003838A1 (en) 1989-05-05
HK1004854A1 (en) 1998-12-11
DK174400B1 (da) 2003-02-10
FI941245A0 (fi) 1994-03-16
EP0355131B1 (en) 1996-09-04
FI893100A0 (fi) 1989-06-26
NO892642D0 (no) 1989-06-26
IN167609B (fi) 1990-11-24
JPH02500373A (ja) 1990-02-08
JP2637534B2 (ja) 1997-08-06
US6020320A (en) 2000-02-01
FI97891B (fi) 1996-11-29
EP0712629A1 (en) 1996-05-22
FI941245A (fi) 1994-03-16
FI97891C (fi) 1997-03-10
ATE243039T1 (de) 2003-07-15
JP2764014B2 (ja) 1998-06-11
NO174392B (no) 1994-01-17
KR890701609A (ko) 1989-12-21
CA1329932C (en) 1994-05-31
ZA888083B (en) 1990-06-27
DE3855513T2 (de) 1997-01-09
ATE142221T1 (de) 1996-09-15
EP0355131A4 (en) 1990-12-05
DK318089D0 (da) 1989-06-27
DK318089A (da) 1989-08-28
DE3856557D1 (de) 2003-07-24
EP0355131A1 (en) 1990-02-28
EP0712629B1 (en) 2003-06-18
FI91764B (fi) 1994-04-29
DE3855513D1 (de) 1996-10-10

Similar Documents

Publication Publication Date Title
FI893100L (fi) Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi
NO850300L (no) Fremgangsmaate for fremstilling av 3-imidazolylmetyl-tetrahydrokarbazolon-derivater
PT88596A (pt) Process for preparing 2-anilinopyrimidine derivatives useful aspesticidas
FI875660L (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi
KR860005811A (ko) 티아졸리딘디온 유도체의 제조방법
NO173498C (no) Analogifremgangsmaate for fremstilling av substituerte 9-amino-tetrahydroakridiner
PT86800A (pt) Process for the preparation of erythromycin derivatives
PT86687A (pt) Process for the preparation of novel polyamine derivatives
NO172447C (no) Fremgangsmaate for fremstilling av b-avermectiner
PT87153A (pt) Process for the preparation of acid ribofuranuronic derivatives
FI95036B (fi) Tieno-triatsolo-diatsepiinijohdosten valmistusmenetelmä
FI91961C (fi) Menetelmä (S)- -etyyli-2-okso-1-pyrrolidiiniasetamidin valmistamiseksi
PT87854A (pt) Process for the preparation of thio-urea derivatives
NO880910D0 (no) Fremgangsmaate for fremstilling av chromonderivater.
NO880294L (no) Fremgangsmaate for fremstilling av tetrahydrofuranderivater
IL88163A0 (en) Method for the preparation of anilopiperidine derivatives
KR870001175A (ko) 5-치환된-6-아미노피리미딘 유도체의 제조방법
PT87359A (pt) Process for the preparation of pyrrolidine derivatives
FI883930L (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten bentsimidatsolijohdannaisten valmistamiseksi
NO884900L (no) Fremgangsmaate for fremstilling av ginkolid-derivater.
NO851550L (no) Fremgangsmaate for fremstilling av imidazolderivater
DK314988A (da) Fremgangsmaade til fremstilling af 6-deoxyguaninderivater
FI91069B (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
FI862234L (fi) Menetelmä 2-karboksipyratsiini-4-oksidien valmistamiseksi
PT87732A (pt) Process for the preparation of (e)-(p-fluorophenethyl)-3-fluoroallylamine

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: PRO-NEURON, INC.

MA Patent expired